1. Introduction {#s0005}
===============

Bezafibrate \[2-(p-(2-(p-chlorobenzamido)ethyl)-phenoxy)-2-methyl propionic acid\] is a peroxisome proliferator-activated receptor agonist \[[@bb0005]\] that decreases serum lipid levels in humans \[[@bb0010],[@bb0015]\]. Recent reports implicated bezafibrate as a promising drug for fatty acid oxidation disorders (FAODs) based on enhanced transcription of several β-oxidation enzymes *in vitro* \[[@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050]\]. We also recently reported on the efficacy of bezafibrate for FAODs in a recent clinical trial \[[@bb0055]\], wherein patients showed improvements in some quality of life (QOL) components during a 6-month survey, but no significant changes in the frequency of myopathic attacks, the levels of creatine kinase (CK) and acylcarnitines (ACs, C14:1 or C16 + C18:1), and visual analog scale (VAS) values during the attacks. We suspected that these endpoints could not be adequately evaluated due to several limitations, including the small trial population. We did however find that QOL showed improvement during the 50-week study. Herein we report on a follow-up study of the trial for more than two years to evaluate the efficacy of bezafibrate for QOL in patients with FAODs.

2. Materials and methods {#s0010}
========================

Our current study is a follow-up of previously reported results \[[@bb0055]\], using the same subjects and study design.

2.1. Design {#s0015}
-----------

This study was a non-randomized, uncontrolled, multicenter, open-label trial.

2.2. Standard protocol approvals, registrations, and patient consents {#s0020}
---------------------------------------------------------------------

The Institutional Review Boards of Hokkaido University Hospital and the other collaborating institutions approved the recent clinical trial. All patients were registered on the database of the Department of Pediatrics, Shimane University Faculty of Medicine. Written informed consent for study participation was obtained from all patients or their parents.

2.3. Setting {#s0025}
------------

The study was conducted at Hokkaido University Hospital Clinical Research and Medical Innovation Center, Japan, and the bezafibrate clinical trial was performed at each collaborating institution. Participants were recruited from January 2014 to December 2015. Bezafibrate was purchased from Kissei Pharmaceutical Co., Ltd., Nagano, Japan.

2.4. Patients {#s0030}
-------------

According to our previous study, we followed up five patients with very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) and a patient with carnitine palmitoyltransferase-II deficiency (CPT2D). Patient profiles are listed in [Table 1](#t0005){ref-type="table"}, with VL-4 and VL-5 reported in detail in previous manuscripts \[[@bb0060],[@bb0065]\].Table 1Clinical features and genotypes of the patients before enrollment.Table 1VL-1VL-2VL-3VL-4VL-5CP-1Age26 y25 y6 y6 y22 y5 ySexFMFMFFDiagnosisVLCADDVLCADDVLCADDVLCADDVLCADDCPT-2DIndustry dose of bezafibrate400 mg/day400 mg/day100 mg/day100 mg/day400 mg/day100 mg/dayStandard dose of bezafibrate600 mg/day600 mg/day200 mg/day200 mg/day600 mg/day200 → 300 mg/dayMutationF113^⁎^UntestedR229XL243FE285GF383YK382QUntestedK382QV547 MV400 MR477WOnset age1.5 y5 moAround 1 y3 yAround 13 y3.7 yDiagnosis age5 y13 y0 mo3 y22 y8 moBody weight (kg)565820214717Clinical featuresMyalgia or fatigueMyalgia or fatigueMyalgia or fatigueMyalgia or rhabdomyolysisMyalgia or rhabdomyolysisRhabdomyolysis or hyper CK  Frequency ofSevere attacks20 /year0Several times /year1--2/year5/year1/yearModerate attacks50--60 /year012 /y07 /year0Mild attacksAlmost every day2/yearUncountable012 /year0  TreatmentsCarnitine (mg/day)750 mg400--600 mgAlmost noneNone1800 mg900--1800 mgMCT oil/milkNoneYesNoneYesNoneNoneRestriction of activityProlonged walk and standingAiringUnclearNoneNoneNoneResponsiveness of bezafibrate in vitroGoodUntestedGoodGoodGoodUntestedCK baseline (IU/L)1933 ± 1220768 ± 6121112 ± 125381 ± 13590 ± 660308 ± 169C14:1 baseline (μM)10.41 ± 4.643.27 ± 4.052.98 ± 0.881.37 ± 1.771.36 ± 0.85C16 + C18:1 baseline (μM)6.94 ± 5.70[^2]

Age brackets were assigned, with three patients aged 3--7.5 years, none aged 7.5--12 years, and the remaining three aged \>12 years.

2.5. Protocol {#s0035}
-------------

As shown in [Fig. 1](#f0005){ref-type="fig"}, the last study comprised 3 periods: 1) a screening period for 4 weeks; 2) an observation period for 24 weeks; and, 3) an administration period for 26 weeks. The administration period was divided into a 2-week introductory period and a 24-week standard treatment period. After the standard treatment period, all patients were invited for follow-up treatment over 28 weeks to evaluate the long-term safety of bezafibrate. The administration and follow-up treatment were conducted as prospective research under the guidance of the Good Clinical Practice (GCP) standard overseen by the Health, Labor and Welfare Ministry of Japan. After the prospective research, six of eight patients proceeded to the clinical study period, wherein QOL was evaluated using a 36-item Short Form Health Survey (SF-36) \[[@bb0070]\] to comprise this current study. The remaining two patients dropped out of the original study cohort due to economic reasons.Fig. 1Study protocol.CP-1 patient was classified as having a severe clinical disease course at the 38th week (12 weeks after starting standard treatment) and was given enhanced-dose bezafibrate.Fig. 1

[Table 1](#t0005){ref-type="table"} details the bezafibrate dosage for each patient. Treatment with standard-dose bezafibrate (200, 300, and 600 mg/day for patients aged 3--7.5, 7.5--12, and \> 12 years, respectively) was initiated and continued for 24 weeks. Enhanced treatment of 400 mg/day was accepted in one patient (CP-1) following no decrease in the frequency of myopathic attacks by the 12th week of treatment. Patient QOL was re-evaluated at the end of the administration period using the SF-36, and then again at weeks 126 (VL-4), 150 (VL-5), 162 (CP-1), 174 (VL-3), 186 (VL-2), and 198 (VL-1). The different evaluation duration for each patient reflected the initiation time of bezafibrate; however, each patient completed the questionnaire at equivalent time points. Drug compliance was calculated as (prescription number -- remainder number)/prescription number.

2.6. Endpoint {#s0040}
-------------

We quantitated QOL using the SF-36 questionnaire to capture the eight components of physical functioning (PF), role limitation due to physical problems (role physical; RP), bodily pain (BP), general health perception (GHP), vitality (VT), social functioning (SF), role limitation due to emotional problems (role emotional; RE), and mental health (MH). An elevated total score indicated improvement in QOL. We have precisely surveyed any adverse effect and assessed the toxicity of bezafibrate.

2.7. Statistical analysis {#s0045}
-------------------------

QOL data were analyzed using a paired *t*-test for comparisons using JMP version 14.3.0 (SAS Institute Inc., Cary, NC, USA). Descriptive statistics (mean ± standard deviation) were used when repeated measurements were obtained. We defined *P* values \<.05 as signifying statistical significant differences.

3. Results {#s0050}
==========

3.1. QOL using the SF-36 questionnaire {#s0055}
--------------------------------------

Results of the QOL questionnaire were obtained after the screening period (baseline), after week 50 (after standard administration), and during the clinical study (long-term evaluation) ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Quality of life evaluation in each patient.Color bars indicate the clinical value: SF-36 scores at baseline, week 50, and at the last survey point, respectively.PF, physical functioning; RP, role limitation due to physical problems; BP, bodily pain; GHP, general health perception; VT, vitality; SF, social functioning; RE, role limitation due to emotional problems; MH, mental health.Fig. 2

In our previous 50-week study, the average total QOL score was significantly elevated after the administration period compared to baseline \[[@bb0055]\]. Herein we similarly found elevated QOL scores from baseline in all cases except VL-3, while the total QOL score over the extended evaluation time was further elevated compared with those at week 50 in VL-1, −2, and − 5 ([Table 2](#t0010){ref-type="table"}). Importantly, the total QOL scores elevated steadily in all patients aged over 20 years: VL-1, VL-2, and VL-5, while showing no significant elevations among cases younger than 20 years ([Table 2](#t0010){ref-type="table"}).Table 2Comparison of the total QOL scores using SF-36 before and after treatment.Table 2AgeBaselineWeek 50Clinical studyOver 20 years oldVL-126y247.4267.8307.5 (198th week)VL-225y392423.4429.4 (186th week)VL-522y371385.8449.6 (150th week)Average336.8359 (*P* = .045 vs. baseline)395.5 (*P* = .038 vs. baseline)\
(*P* = .161 vs. week 50)  Under 20 years oldVL-36y381.3415.5362.7 (174th week)VL-46y271.5353.5347.0 (126th week)CP-15y379.7400.2388.2 (162nd week)Average344.2389.7 (*P* = .134 vs. baseline)366.0 (*P* = .517 vs. baseline)\
(*P* = .245 vs. week 50)Total Average340.5374.4 (*P* = .020 vs. baseline)380.7 (*P* = .053 vs. baseline; *P* = .719 vs. week 50)[^3]

This survey revealed maintenance of the improvement over a long-term evaluation for all QOL components with the exception of RE ([Table 3](#t0015){ref-type="table"}); however, the results of this clinical study were not significantly improved compared with those over 50 weeks.Table 3Averaged QOL results from the SF-36 administered before and after treatment.Table 3BaselineWeek 50 (*P-*value vs. baseline)Clinical study (*P-*value vs. baseline)*P-*value: week 50 vs. clinical studyPhysical functioning (*n* = 6)42.249.4 (*P* ≤ .01)50.6 (*P* = .003)0.175Physical role (*n* = 6)38.043.0 (*P* = .019)42.4 (*P* = .224)0.897Bodily pain (*n* = 6)39.741.9 (*P* = .109)47.7 (*P* = .151)0.130General health perceptions (*n* = 5)42.245.3 (*P* = .354)46.5 (*P* = .041)0.117Vitality (*n* = 6)46.149.3 (*P* = .194)50.4 (*P* = .329)0.767Social functioning (*n* = 6)42.049.5 (*P* = .033)48.4 (*P* = .041)0.821Emotional role (*n* = 6)45.746.4 (*P* = .315)45.0 (*P* = .869)0.775Mental health (*n* = 6)51.457.2 (*P* = .070)55.9 (*P* = .094)0.726

3.2. Safety and toxicity of bezafibrate {#s0060}
---------------------------------------

A patient took herpangina during the 24-week observation period prior to the administration period. This issue does not affect the current results since bezafibrate was not used. Other patients kept using bezafibrate without any adverse effect or toxicity to liver and kidney function. Levels of total cholesterol remained within normal limits.

4. Discussion {#s0065}
=============

A French group undertook the first study of bezafibrate treatment for FAODs \[[@bb0045]\]. Based on that work, we undertook the next prospective clinical study in compliance with GCP standards and as officially approved by the Health, Labor and Welfare Ministry of Japan \[[@bb0025],[@bb0055]\]. Our findings revealed a short-term efficacy for bezafibrate in patients with FAODs and suggested that the subjective QOL of patients was improved during the 50-week study. Herein, we report a longer-term, follow-up study wherein we continued to administer bezafibrate after the initial 50-week period (completion of the previous trial) and continued monitoring of QOL using the SF-36 questionnaire. In five of the six cases, QOL improved by \>50% across all quality sub-components. Two patients showed QOL improvement in all sub-components, while all cases aged over 20 years including a 25-year-old showed remarkable QOL improvement. In particular, one patient assessed as a non-responder to bezafibrate in the original study showed a remarkable improvement in QOL score during this follow-up study. Specifically, her number of hospitalizations decreased, and she showed a response to bezafibrate, suggesting that long-term administration is needed to achieve a benefit for some patients with FAODs. Our results also suggested that the effect of bezafibrate on QOL continued for at least 2 years.

In contrast, cases under the age of 20 years, and particularly those under 10 years, showed a decreased score for some QOL sub-components, despite their caregiver reporting that daily activity and exercise increased accordingly in these patients. The decrease in some aspects of QOL in the younger participants might therefore reflect their increased general activity even if bezafibrate suppressed the metabolic attacks. In addition, no cases refused to continue taking bezafibrate, suggesting that participant and/or their caregivers recognized the efficacy of bezafibrate. In general, an effective drug for movement disorder or neuropraxia should gain activity for the patient. Thus, an appropriate and objective procedure should be established to assess the efficacy of new drugs for FAOD. For example, objective assessment of daily activity including length of walking ability and duration of exercise might be a suitable method for assessing the efficacy of some drugs for patients with FAOD.

Our previous study found no improvement in CPK level during myopathic attack, Visual Analog Scale scores, or acylcarnitine concentrations from bezafibrate treatment in this population. One problem with the previous manuscript was the definition of myopathic attack as when patients show a 5-fold increase over baseline CK levels; however, the levels tended to increase gradually for 4 days, so complaint of myopathic attack could not be confirmed, even when the patients complained of general fatigue or myalgia, and visited the hospital for treatment. So, we should ignore real myopathic attack and the assessment of AC should not be promising. In this way, the primary endpoint of our previous study was not defined statistically.

To adequately assess the efficacy of a new drug for FAOD, we therefore need a new technique that demonstrates changes in mitochondrial function directly. Bastin et al. tried to assess the efficacy of drugs based on myoblast cell activity from a biopsy collected before and after administration of bezafibrate; however, this procedure would be too invasive for enrolled patients. Another possible new technique is direct observation of mitochondria using immunoluminescence analysis. Murchison et al. demonstrated that voltage-clamp electrophysiology with Ca2^+^-sensitive ratiometric microfluorimetry and laser scanning confocal microscopy showed the participation in Ca2^+^ buffering of in situ mitochondria in a model rat with mitochondrial dysfunction \[[@bb0075]\]. A potential-dependent, J-aggregate-forming, delocalized lipophilic cation, 5,5′,6,6′-tetrachloro- 1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide (JC-1), is another promising procedure that shows membrane potentials across mitochondria in a living cell \[[@bb0080]\]. Although these techniques require a fibroblast biopsy for subjective patients, they should still be tested to assess mitochondrial function.

There remains no effective cure for FAODs, and adequate ingestion of carbohydrates with administration of MCT milk is regarded as the only treatment \[[@bb0085]\]. An earlier clinical trial showed the in vitro efficacy of bezafibrate to treat FAODs, and we believe that the present findings will further help patients adapt to bezafibrate therapy \[[@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050]\]. In addition, no adverse events have been recorded for bezafibrate thus far. Finally, we could not fully discount the possibility of placebo effect in this study, since we evaluated subjective QOL using an open-label survey.

5. Conclusion {#s0070}
=============

Our study indicated that bezafibrate treatment might be effective in improving QOL for patients with FAODs for over 2 years without adverse effects.
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